Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2023, Vol. 43 Issue (7): 1-11    DOI: 10.13523/j.cb.2301030
    
Analysis of Amino Acid Sites for HEV Binding to Cells
Ya-jie LIN,Chang LIU,Shao-qi GUO,Zi-hao YU,Ming-yu LI,Jun-fei LIU,Zi-zheng ZHENG*(),Ning-shao XIA
National Institute of Diagnostics and Vaccine Development in Infections Diseases, School of Public Health, Xiamen University, Xiamen 361102, China
Download: HTML   PDF(3488KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: In this study, we constructed a model for evaluating the binding of hepatitis E virus (HEV) mutated capsid proteins to cells in a way that allowed us to evaluate the role of various amino acid sites in the cell binding process. This method helps us understand the invasion mechanism of HEV and lays a foundation for studying the receptor of HEV. Methods: We used a genotype IV recombinant virus-like particle-like antigen called D66, which contains the key domain of a.a.459-606.We performed site-specific mutations of amino acids at key D66 domain sites, and then confirmed the normal conformation of all mutated proteins by SDS-PAGE and ELISA methods. After confirming the conformation of the mutated proteins, we analyzed the effect of these mutated proteins on adsorption by flow cytometry to find out the key sites that affect the absorption of virus into the cell. Results: We successfully prepared and ide.pngied 45 correctly folded and conformationally normal mutant proteins by polymerase chain reaction site-specific mutagenesis. ELISA results showed that the single point mutation of recombinant viral particle-like antigen D66 did not affect the conformation of the protein. In the application of the model to simulate the binding process of mutant proteins to cells, we found that the mutant proteins of T484A, S488A, T489A, P491A, R512A, Y561A, N562A and T585A significantly affected their adsorption of C3A. Conclusion: In this study, a model was established to evaluate the cell binding of HEV capsid protein, and it was found that alanine mutations at T484A, S488A, T489A, P491A and R512A significantly weakened the cell binding of HEV capsid proteins. These sites may be the key sites that affect HEV binding to cells.



Key wordsHEV      Single point mutant protein      Genotype IV recombinant virus-like particle antigen D66 protein     
Received: 18 January 2023      Published: 03 August 2023
ZTFLH:  Q819  
Cite this article:

Ya-jie LIN, Chang LIU, Shao-qi GUO, Zi-hao YU, Ming-yu LI, Jun-fei LIU, Zi-zheng ZHENG, Ning-shao XIA. Analysis of Amino Acid Sites for HEV Binding to Cells. China Biotechnology, 2023, 43(7): 1-11.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2301030     OR     https://manu60.magtech.com.cn/biotech/Y2023/V43/I7/1

Fig.1 Continuous truncated proteins of pORF2 are shown by bar
Fig.2 SDS-PAGE of single point mutant protein
Fig.3 Reactivity of 3 mAbs with 45 alanine scanning mutants
Fig.4 Binding capability of the mutant proteins to C3A cells (a) The table shows the positive proportion of binding for each mutant protein (b) The black dotted line is the NC group, the blue area represents the mutant protein, and the green area represents the wild D66 protein. The combination of scale is indicated in each diagram
Fig.5 Amino acid residues involved in the binding to C3A cells Surface maps of capsid protein dimers from transverse (80 degree rotation on the X-axis) and longitudinal (90 degree rotation on the Y-axis) show amino acid sites that significantly influence binding. Eight amino acid sites in HEV-LP that significantly affect binding to C3A cells (T484A, S488A, T489A, P491A, R512A, Y561A, N562A, T585A) are shown in red. Amino acid sites in the HEV-LP domain that have no significant effect on binding to C3A cells are shown in dark gray
Fig.6 Effect of heparin on the binding capability of the mutant proteins to C3A cells (a) C3A cells were treated with different concentrations of heparinase. The treatment concentration of each group is shown on the right side of the figure, with darker colors indicating higher residual HSPG content (b) The table shows the positive proportion of the two experimental groups (c) The black dotted line represents the NC group, the blue area represents the group where the cells were pre-incubated with heparin/the group where the cells were pre-treated with heparin III, and the green area represents the wild D66 protein. The combination of scale is indicated in each diagram
Fig.7 Binding capability of the mutant proteins to C3A cells The black dotted line is the NC group, the blue area represents the mutant protein, and the green area represents the wild D66 protein. The combination of scale is indicated in each diagram
[1]   Panda S K, Thakral D, Rehman S. Hepatitis E virus. Reviews in Medical Virology, 2007, 17(3): 151-180.
doi: 10.1002/rmv.522 pmid: 17051624
[2]   Purcell R H, Emerson S U. Hepatitis E: an emerging awareness of an old disease. Journal of Hepatology, 2008, 48(3): 494-503.
doi: 10.1016/j.jhep.2007.12.008 pmid: 18192058
[3]   Kamar N, Izopet J, Pavio N, et al. Hepatitis E virus infection. Nature Reviews Disease Primers, 2017, 3: 17086.
doi: 10.1038/nrdp.2017.86 pmid: 29154369
[4]   Jaiswal S P B, Jain A K, Naik G, et al. Viral hepatitis during pregnancy. International Journal of Gynecology & Obstetrics, 2001, 72(2): 103-108.
[5]   张文. 戊型肝炎分子流行病学及其病原与宿主细胞互作机制研究. 上海: 上海交通大学, 2009.
[5]   Zhang W. Study of the molecular epidemiology of hepatitis E and the inferaction mechanism between HEV and its host. Shanghai: Shanghai Jiao Tong University, 2009.
[6]   Pavio N, Renou C, Liberto G D, et al. Hepatitis E: a curious zoonosis. Frontiers in Bioscience, 2008, 13: 7172-7183.
[7]   王葳, 陈恺韵, 吴立梦, 等. 2017-2020年上海市戊型肝炎病毒基因型特征研究. 疾病监测, 2022, 37(2): 214-219.
[7]   Wang W, Chen K Y, Wu L M, et al. Genetic characteristics of hepatitis E in Shanghai, 2017-2020. Disease Surveillance, 2022, 37(2): 214-219.
[8]   Liu P, Li L J, Wang L, et al. Phylogenetic analysis of 626 hepatitis E virus (HEV) isolates from humans and animals in China (1986-2011) showing genotype diversity and zoonotic transmission. Infection, Genetics and Evolution, 2012, 12(2): 428-434.
doi: 10.1016/j.meegid.2012.01.017
[9]   Balayart M S, Andjaparidze A G, Savinskaya S S, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology, 1983, 20(1): 23-31.
doi: 10.1159/000149370 pmid: 6409836
[10]   Nagashima S, Takahashi M, Kobayashi T, et al. Characterization of the quasi-enveloped hepatitis E virus particles released by the cellular exosomal pathway. Journal of Virology, 2017, 91(22): e00822-17.
[11]   Takahashi M, Tanaka T, Takahashi H, et al. Hepatitis E Virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: characterization of HEV virions in blood circulation. Journal of Clinical Microbiology, 2010, 48(4): 1112-1125.
doi: 10.1128/JCM.02002-09 pmid: 20107086
[12]   Yin X, Ambardekar C, Lu Y R, et al. Distinct entry mechanisms for nonenveloped and quasi-enveloped hepatitis E viruses. Journal of Virology, 2016, 90(8): 4232-4242.
doi: 10.1128/JVI.02804-15 pmid: 26865708
[13]   Chapuy-Regaud S, Dubois M, Plisson-Chastang C, et al. Characterization of the lipid envelope of exosome encapsulated HEV particles protected from the immune response. Biochimie, 2017, 141: 70-79.
doi: S0300-9084(17)30115-3 pmid: 28483690
[14]   Reyes G R, Purdy M A, Kim J, et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science, 1990, 247(4948): 1335-1339.
pmid: 2107574
[15]   Tam A W, Smith M M, Guerra M E, et al. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology, 1991, 185(1): 120-131.
doi: 10.1016/0042-6822(91)90760-9 pmid: 1926770
[16]   Reyes G R, Yarbough P O, Tam A W, et al. Hepatitis E virus (HEV): the novel agent responsible for enterically transmitted non-A, non-B hepatitis. Gastroenterologia Japonica, 1991, 26(3): 142-147.
doi: 10.1007/BF02779285
[17]   Koonin E V, Gorbalenya A E, Purdy M A, et al. Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89(17): 8259-8263.
[18]   Korkaya H, Jameel S, Gupta D, et al. The ORF3 protein of hepatitis E virus binds to src homology 3 domains and activates MAPK. Journal of Biological Chemistry, 2001, 276(45): 42389-42400.
doi: 10.1074/jbc.M101546200 pmid: 11518702
[19]   Nagashima S, Takahashi M, Jirintai S, et al. Tumour susceptibility gene 101 and the vacuolar protein sorting pathway are required for the release of hepatitis E virions. Journal of General Virology, 2011, 92(12): 2838-2848.
doi: 10.1099/vir.0.035378-0
[20]   Yamada K, Takahashi M, Hoshino Y, et al. ORF3 protein of hepatitis E virus is essential for virion release from infected cells. Journal of General Virology, 2009, 90(8): 1880-1891.
doi: 10.1099/vir.0.010561-0
[21]   Emerson S U, Nguyen H T, Torian U, et al. Release of genotype 1 hepatitis E virus from cultured hepatoma and polarized intestinal cells depends on open reading frame 3 protein and requires an intact PXXP m. png. Journal of Virology, 2010, 84(18): 9059-9069.
[22]   Takahashi M, Yamada K, Hoshino Y, et al. Monoclonal antibodies raised against the ORF 3 protein of hepatitis E virus (HEV) can capture HEV particles in culture supernatant and serum but not those in feces. Archives of Virology, 2008, 153(9): 1703-1713.
doi: 10.1007/s00705-008-0179-6 pmid: 18679765
[23]   Li T C, Yamakawa Y, Suzuki K, et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus. Journal of Virology, 1997, 71(10): 7207-7213.
pmid: 9311793
[24]   Mushahwar I K, Dawson G J, Reyes G R. Hepatitis E virus: molecular biology and diagnosis. European Journal of Gastroenterology & Hepatology, 1996, 8(4): 312-318.
[25]   Reyes G R, Huang C C, Tam A W, et al. Molecular organization and replication of hepatitis E virus (HEV). Archives of Virology Supplementum, 1993, 7: 15-25.
[26]   林庆山, 蒋婕, 李婷婷, 等. 杆状病毒-昆虫细胞系统表达的戊型肝炎病毒衣壳蛋白p495的纯化、结构解析以及免疫原性分析. 病毒学报, 2016, 32(3): 342-348.
[26]   Lin Q S, Jiang J, Li T T, et al. Expression, purification, structure determination and immunogenicity assay of hepatitis E virus capsid protein p 495 derived from baculovirus-based insect cell. Chinese Journal of Virology, 2016, 32(3): 342-348.
[27]   Wei M X, Zhang X, Yu H, et al. Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes. Vaccine, 2014, 32(24): 2859-2865.
doi: 10.1016/j.vaccine.2014.02.025 pmid: 24662711
[28]   Zhang J, Gu Y, Ge S X, et al. Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein. Vaccine, 2005, 23(22): 2881-2892.
pmid: 15780737
[29]   Zhang J Z, Ng M H, Xia N S, et al. Conformational antigenic determinants generated by interactions between a bacterially expressed recombinant peptide of the hepatitis E virus structural protein. Journal of Medical Virology, 2001, 64(2): 125-132.
pmid: 11360244
[30]   Li S W, Zhang J, Li Y M, et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine, 2005, 23(22): 2893-2901.
pmid: 15780738
[31]   Li S W, Tang X H, Seetharaman J, et al. Dimerization of hepatitis E virus capsid protein E2s domain is essential for virus-host interaction. PLoS Pathogens, 2009, 5(8): e1000537.
doi: 10.1371/journal.ppat.1000537
[32]   Zhang J, Li S W, Wu T, et al. Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity. Reviews in Medical Virology, 2012, 22(5): 339-349.
doi: 10.1002/rmv.1719 pmid: 22645002
[33]   何志强, 张军, 李少伟, 等. 颗粒化重组戊型肝炎病毒衣壳蛋白及其抗原性与免疫原性. 生物工程学报, 2004, 20(2): 262-268.
[33]   He Z Q, Zhang J, Li S W, et al. Particulate recombinant hepatitis E virus capsid protein and its antigenicity and immunogenicity. Chinese Journal of Biotechnology, 2004, 20(2): 262-268.
[34]   何水珍, 郑子峥, 吴婷, 等. 戊型肝炎病毒细胞吸附模型的建立及病毒吸附区域初步研究. 病毒学报, 2006, 22(6): 426-430.
[34]   He S Z, Zheng Z Z, Wu T, et al. The establishment of cellular attachment model for hepatitis E virus (HEV) and its application in the ide.pngication of HEV cellular attachment region. Chinese Journal of Virology, 2006, 22(6): 426-430.
[35]   Emerson S U, Nguyen H, Graff J, et al. In vitro replication of hepatitis E virus (HEV) genomes and of an HEV replicon expressing green fluorescent protein. Journal of Virology, 2004, 78(9): 4838-4846.
doi: 10.1128/JVI.78.9.4838-4846.2004
[36]   Li S W, Zhang J, He Z Q, et al. Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid. Journal of Biological Chemistry, 2005, 280(5): 3400-3406.
doi: 10.1074/jbc.M410361200
[37]   Kalia M, Chandra V, Rahman S A, et al. Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF 2 capsid protein and for viral infection. Journal of Virology, 2009, 83(24): 12714-12724.
doi: 10.1128/JVI.00717-09